JPWO2020061293A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020061293A5 JPWO2020061293A5 JP2021515616A JP2021515616A JPWO2020061293A5 JP WO2020061293 A5 JPWO2020061293 A5 JP WO2020061293A5 JP 2021515616 A JP2021515616 A JP 2021515616A JP 2021515616 A JP2021515616 A JP 2021515616A JP WO2020061293 A5 JPWO2020061293 A5 JP WO2020061293A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- composition
- prostate cancer
- contrast agent
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023204832A JP7748438B2 (ja) | 2018-09-21 | 2023-12-04 | シールド剤およびそれらの使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862734690P | 2018-09-21 | 2018-09-21 | |
| US62/734,690 | 2018-09-21 | ||
| PCT/US2019/051903 WO2020061293A1 (en) | 2018-09-21 | 2019-09-19 | Shielding agents and their use |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023204832A Division JP7748438B2 (ja) | 2018-09-21 | 2023-12-04 | シールド剤およびそれらの使用 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022501383A JP2022501383A (ja) | 2022-01-06 |
| JPWO2020061293A5 true JPWO2020061293A5 (https=) | 2022-09-29 |
| JP2022501383A5 JP2022501383A5 (https=) | 2022-09-29 |
| JP7429688B2 JP7429688B2 (ja) | 2024-02-08 |
Family
ID=69887812
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021515616A Active JP7429688B2 (ja) | 2018-09-21 | 2019-09-19 | シールド剤およびそれらの使用 |
| JP2023204832A Active JP7748438B2 (ja) | 2018-09-21 | 2023-12-04 | シールド剤およびそれらの使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023204832A Active JP7748438B2 (ja) | 2018-09-21 | 2023-12-04 | シールド剤およびそれらの使用 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20210323985A1 (https=) |
| EP (1) | EP3853213A4 (https=) |
| JP (2) | JP7429688B2 (https=) |
| CN (1) | CN113166087B (https=) |
| WO (1) | WO2020061293A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112015011118B1 (pt) * | 2012-11-15 | 2022-12-13 | Endocyte, Inc | Conjugado; composição farmacêutica; e uso de um conjugado |
| BR112016010927A2 (pt) | 2013-11-14 | 2017-08-08 | Endocyte Inc | Conjugado de fórmula |
| US12208102B2 (en) | 2018-04-17 | 2025-01-28 | Endocyte, Inc. | Methods of treating cancer |
| CN114096264B (zh) | 2019-05-20 | 2025-03-14 | 因多塞特股份有限公司 | 制备psma缀合物的方法 |
| CA3237590A1 (en) * | 2021-11-09 | 2023-05-08 | James Basilion | Psma targeted conjugate compounds and uses thereof |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2847275T3 (es) * | 2006-11-08 | 2021-08-02 | Molecular Insight Pharm Inc | Heterodímeros de ácido glutámico |
| EP4464384A3 (en) | 2007-08-17 | 2025-01-08 | Purdue Research Foundation | Psma binding ligand-linker conjugates and methods for using |
| WO2012174136A1 (en) * | 2011-06-15 | 2012-12-20 | Cancer Targeted Technology Llc | Chelated psma inhibitors |
| BR112015011118B1 (pt) * | 2012-11-15 | 2022-12-13 | Endocyte, Inc | Conjugado; composição farmacêutica; e uso de um conjugado |
| LT4095130T (lt) * | 2013-10-18 | 2024-04-25 | Novartis Ag | Žymėti prostatos specifinio membranos antigeno (psma) inhibitoriai, jų naudojimas kaip vizualizavimo medžiagų ir farmacinių medžiagų prostatos vėžiui gydyti |
| US9988407B2 (en) | 2014-08-06 | 2018-06-05 | The Johns Hopkins University | Prodrugs of prostate specific membrane antigen (PSMA) inhibitor |
| AU2015315465B2 (en) | 2014-09-08 | 2019-08-29 | Molecular Insight Pharmaceuticals, Inc. | Organ protection in PSMA-targeted radionuclide therapy of prostate cancer |
| SG11201909513QA (en) | 2017-04-11 | 2019-11-28 | Univ Johns Hopkins | Prodrugs of 2-pmpa for healthy tissue protection during psma-targeted cancer imaging or radiotherapy |
-
2019
- 2019-09-19 EP EP19863710.0A patent/EP3853213A4/en active Pending
- 2019-09-19 CN CN201980076992.7A patent/CN113166087B/zh active Active
- 2019-09-19 JP JP2021515616A patent/JP7429688B2/ja active Active
- 2019-09-19 WO PCT/US2019/051903 patent/WO2020061293A1/en not_active Ceased
- 2019-09-19 US US17/277,806 patent/US20210323985A1/en active Pending
-
2023
- 2023-12-04 JP JP2023204832A patent/JP7748438B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Altunay et al. | HER2-directed antibodies, affibodies and nanobodies as drug-delivery vehicles in breast cancer with a specific focus on radioimmunotherapy and radioimmunoimaging | |
| JP2022501383A5 (https=) | ||
| Song et al. | Radioimmunotherapy of breast cancer metastases with α-particle emitter 225Ac: comparing efficacy with 213Bi and 90Y | |
| DeNardo | Radioimmunodetection and therapy of breast cancer | |
| Maraveyas et al. | Pharmacokinetics and toxicity of an yttrium‐90‐citc‐dtpa‐hmfg1 radioimmunoconjugate for intraperitoneal radioimmunotherapy of ovarian cancer | |
| JP2010508292A5 (https=) | ||
| Allen | Clinical trials of targeted alpha therapy for cancer | |
| Rowlinson et al. | Antibody-guided localization of intraperitoneal tumors following intraperitoneal or intravenous antibody administration | |
| Loke et al. | Dosimetric considerations in radioimmunotherapy and systemic radionuclide therapies: a review | |
| JPWO2020061293A5 (https=) | ||
| Illidge et al. | Radioimmunotherapy in follicular lymphoma | |
| Grana et al. | Radioimmunotherapy in advanced ovarian cancer: is there a role for pre-targeting with 90Y-biotin? | |
| Li et al. | The experimental study on the radioimmunotherapy of the nasopharyngeal carcinoma overexpressing HER2/neu in nude mice model with intratumoral injection of 188Re-herceptin | |
| Buchsbaum | Experimental radioimmunotherapy | |
| Burvenich et al. | Biodistribution and planar gamma camera imaging of 123I-and 131I-labeled F (ab′) 2 and Fab fragments of monoclonal antibody 14C5 in nude mice bearing an A549 lung tumor | |
| Chen et al. | In vivo examination of 188Re (I)-tricarbonyl-labeled trastuzumab to target HER2-overexpressing breast cancer | |
| Izard et al. | An improved method for labeling monoclonal antibodies with samarium-153: use of the bifunctional chelate 2-(p-isothiocyanatobenzyl)-6-methyldiethylenetriaminepentaacetic acid | |
| Dearling et al. | Technological advances in radioimmunotherapy | |
| Yoo et al. | Small hepatocellular carcinoma: high dose internal radiation therapy with superselective intra-arterial injection of I-131-labeled Lipiodol | |
| US20210236664A1 (en) | Alpha particle formulations for treatment of solid tumors | |
| Rogers et al. | Intraperitoneal radioimmunotherapy with a humanized anti-TAG-72 (CC49) antibody with a deleted CH2 region | |
| Riva et al. | Radioimmunotherapy of CMS Malignant Gliomas by Direct Intralesional Injection of Specific 131| Radiolabeled Monoclonal Antibodies | |
| Camacho et al. | 177Lu-DOTA-Bevacizumab: Radioimmunotherapy agent for melanoma | |
| Hauck et al. | Enhanced tumour uptake of radiolabelled antibodies by hyperthermia: Part I: Timing of injection relative to hyperthermia | |
| JP7239662B2 (ja) | 複合体、造影剤、及びｃｘｃｒ４関連疾患を治療又は診断するための医薬品 |